Navigation Links
Poniard Pharmaceuticals Announces $6.5 Million Financing
Date:12/22/2009

hat are resistant to existing platinum-based cancer therapies. Clinical studies to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Poniard has completed a pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of patients with small cell lung cancer. The Company is also conducting separate Phase 2 trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant (hormone-refractory) prostate cancer. Additionally, Poniard has completed a Phase 1 cardiac safety trial of picoplatin and a Phase 1 study evaluating the oral formulation of picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements, including statements about the Company's financial condition and prospects, the sufficiency of current capital resources and the planned use of capital.. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including, but not limited to, the Company's anticipated operating losses and need for future capital; the risk that future financing alternatives may not be available on favorable terms or at all, the potential safety and efficacy of the Company's picoplatin product candidates; the receipt and timing of any FDA and other required regulatory approvals, if any; if regulatory approval of any product candidate is received, the market's acceptance of that product or the occurrence post-approval problems that ma
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... Netherlands (PRWEB) September 20, 2014 ... technologies to perform a groundbreaking surgery at the specialized ... the mare's superficial digital flexor tendon was ruptured 90% ... kind of injury is a death sentence for a ... America stem cell treatments . This revolutionary ...
(Date:9/19/2014)... Chips that use light, rather than electricity, to ... and energy efficiency is a growing concern as ... chief components of optical circuits light emitters, ... to build. One promising light source for optical ... optical properties when deposited as a single, atom-thick ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
(Date:9/19/2014)... Cereal grain scientists, quality regulators, ... October 5–8, 2014, for the AACC International (AACCI) ... in Providence, Rhode Island. The comprehensive scientific program ... scientists, chemists, microbiologists, nutritionists, and those interested in ... To date, 1,000 attendees have registered for the ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3
... Elekta Neuromag(R),the world-leading equipment for non-invasive ... has been ordered by The,Nebraska Medical Center ... ), With a reputation for excellence, ... Center has earned J.D. Power and Associates,Hospital ...
... response to the,recent comments by certain plaintiff law firms ... (the "Company") (OTC,Bulletin Board: CCYG) asserts that the pending ... so in a court of law. To that end, ... LLP as its counsel and,will defend itself vigorously in ...
... Inc. (Nasdaq: CALP ) today announced that ... Mid Cap Growth Conference in Naples, Florida,will be ... EST. Kevin,Hrusovsky, President and CEO of Caliper, will ... live webcast can be accessed at, http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=CALP&item_id=17485 ,73. ...
Cached Biology Technology:Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 2Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 3CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 2CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 3
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/19/2014)... 2014 Nxt-ID, Inc. (Nasdaq: NXTD and ... the growing m-commerce market, updates the "Wocket in Your Pocket" celebrity ... and light middleweight weight classes, Vinny Pazienza (PAZ). ... Game of Thrones actor Ciaran Hinds and ... star Katey Sagal have been cast in Bleed ...
(Date:9/18/2014)... State University researchers have developed a unique method to ... cleanup in rural areas. , The first microbe-powered, ... and quick way to clean up waste from large ... pollution. , Professor Haluk Beyenal and graduate student ... Architecture discuss the system in the online edition of ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Researchers develop unique waste cleanup for rural areas 2
... laboratory mice that bear aggressive human breast cancers, UC ... growth of tumors -- without damage to surrounding healthy ... issue of the Journal of Nuclear Medicine. , "We ... mice. The next step will be clinical testing in ...
... of hearing have found an underlying molecular cause for ... deafness and the organization of liquid crystals, which are ... the inner ear, sound waves cause the basilar membrane ... trigger nerve impulses that are transmitted to the brain. ...
... in collaboration with colleagues from UC Berkeley and StrataGent ... novel pulsed microjet system engineered to deliver protein drugs ... deeper penetration injection systems cause. The research was published ... of Sciences. , The effort to create needle-free ...
Cached Biology News:UC Davis researchers use heated nanoprobes to destroy breast cancer cells in mice 2Scientists identify molecular cause for one form of deafness 2Researchers design pulsed mircrojet system to deliver protein drugs without pain or bruising 2
Porcine Coronary Artery Endothelial Cells (PCAEC) (>500,000 cells)...
Proliferin (N-14)...
Recognizes the ~115 kDa NMDA receptor NR1 subunit in rat cortex tissue extracts....
... Ligase catalyzes the formation of phosphodiester bonds ... DNAs with 3' hydroxyl and 5' phosphate ... optimizes ligation which can be performed in ... not substrates for this enzyme. A ...
Biology Products: